Standard of Care Treatment

( DrugBank: - / KEGG DRUG: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
53	Sjogren syndrome	2
245	Propionic acidemia	1

ID	Disease name (Link within this page)	Number of trials
246	Methylmalonic acidemia	1

53. Sjogren syndrome

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2031210484	30/03/2022	14/12/2021	A Study of Nipocalimab in Adults with Primary Sjogren'sSyndrome (pSS)	A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety ...	Sjogren's Syndrome	Placebo Placebo infusion will be administered intravenously. Nipocalimab Nipocalimab dose 1 and dose 2 ...	Nishikawa Kazuko	NULL	Recruiting	>= 18age old	<= 75age old	Both	150	Phase 2	Germany;Spain;Italy;Netherlands;Poland;Portugal;United States Of America;France;Taiwan;Japan
2	NCT04968912 (ClinicalTrials.gov)	September 21, 2021	9/7/2021	A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)	A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety ...	Sjogren's Syndrome	Other: Placebo;Drug: Nipocalimab;Drug: Standard of Care Treatment	Janssen Research & Development, LLC	NULL	Recruiting	18 Years	75 Years	All	150	Phase 2	United States;France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan

Clinical trials : 13 / Drugs : 16 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 6

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01599286 (ClinicalTrials.gov)	September 2012	11/5/2012	Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia	Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia	Propionic Acidemia, Type I and/or Type II;Methylmalonic Acidemia;Carbamoyl-Phosphate Synthase I Defi ...	Drug: Carbaglu;Drug: Placebo;Drug: Standard of Care Treatment	Mendel Tuchman	Children's National Research Institute;Boston Children's Hospital;University Hospitals Cleveland Med ...	Active, not recruiting	N/A	99 Years	All	114	Phase 2	United States

Clinical trials : 23 / Drugs : 31 - (DrugBank : 8) / Drug target genes : 17 - Drug target pathways : 23

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01599286 (ClinicalTrials.gov)	September 2012	11/5/2012	Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia	Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia	Propionic Acidemia, Type I and/or Type II;Methylmalonic Acidemia;Carbamoyl-Phosphate Synthase I Defi ...	Drug: Carbaglu;Drug: Placebo;Drug: Standard of Care Treatment	Mendel Tuchman	Children's National Research Institute;Boston Children's Hospital;University Hospitals Cleveland Med ...	Active, not recruiting	N/A	99 Years	All	114	Phase 2	United States